Evaluation of the Parasight Platform for Malaria Diagnosis.

Yochay Eshel¹, Arnon Houri-Yafin¹, Hagai Benkuzari¹, Natalie Lezmy¹, Mamta Soni², Malini Charles², Jayanthi Swaminathan³, Hilda Solomon³, Pavithra Sampathkumar², Zul Premji⁴, Caroline Mbithi⁴, Zaitun Nneka⁴, Simon Onsongo⁴, Daniel Maina⁴, Sarah Levy-Schreier¹, Caitlin Lee Cohen¹, Dan Gluck¹, Joseph Joel Pollak¹, Seth J Salpeter⁵

¹Sight Diagnostics Ltd., Jerusalem, Israel.

²Department of Pathology, Apollo Hospital, Chennai, India.

³Apollo Research and Innovations, Apollo Hospital, Chennai, India.

⁴Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya.

⁵Sight Diagnostics Ltd., Jerusalem, Israel seth@sightdx.com.

PubMed PMC DOI PDF

Abstract

The World Health Organization estimates that nearly 500 million malaria tests are performed annually. While microscopy and rapid diagnostic tests (RDTs) are the main diagnostic approaches, no single method is inexpensive, rapid, and highly accurate. Two recent studies from our group have demonstrated a prototype computer vision platform that meets those needs. Here we present the results from two…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.